vs
LEE ENTERPRISES, Inc（LEE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
LEE ENTERPRISES, Inc的季度营收约是再鼎医药的1.0倍（$130.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs -10.0%），LEE ENTERPRISES, Inc自由现金流更多（$3.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -5.8%）
李企业是一家上市美国传媒企业，在全美25个州运营着72份日报，同时还经营超过350份周报、分类广告刊物及各类专业刊物。公司由阿尔弗雷德·威尔逊·李于1890年创立，总部坐落于爱荷华州达文波特。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LEE vs ZLAB — 直观对比
营收规模更大
LEE
是对方的1.0倍
$127.1M
营收增速更快
ZLAB
高出27.1%
-10.0%
自由现金流更多
LEE
多$30.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-5.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $130.1M | $127.1M |
| 净利润 | $-5.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 4.0% | -54.6% |
| 净利率 | -4.3% | — |
| 营收同比 | -10.0% | 17.1% |
| 净利润同比 | 66.5% | — |
| 每股收益（稀释后） | $-0.92 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LEEZLAB
| Q4 25 | $130.1M | $127.1M | ||
| Q3 25 | $139.1M | $115.4M | ||
| Q2 25 | $141.3M | $109.1M | ||
| Q1 25 | $137.4M | $105.7M | ||
| Q4 24 | $144.6M | $108.5M | ||
| Q3 24 | $158.6M | $101.8M | ||
| Q2 24 | $150.6M | $100.1M | ||
| Q1 24 | $146.6M | $87.1M |
净利润LEEZLAB
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $-6.4M | $-36.0M | ||
| Q2 25 | $-1.9M | $-40.7M | ||
| Q1 25 | $-12.5M | $-48.4M | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-10.1M | $-41.7M | ||
| Q2 24 | $-4.3M | $-80.3M | ||
| Q1 24 | $-12.2M | $-53.5M |
毛利率LEEZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率LEEZLAB
| Q4 25 | 4.0% | -54.6% | ||
| Q3 25 | -1.0% | -42.3% | ||
| Q2 25 | 3.3% | -50.3% | ||
| Q1 25 | -3.3% | -53.3% | ||
| Q4 24 | -2.3% | -62.6% | ||
| Q3 24 | -2.3% | -66.6% | ||
| Q2 24 | 3.3% | -76.0% | ||
| Q1 24 | -3.1% | -80.7% |
净利率LEEZLAB
| Q4 25 | -4.3% | — | ||
| Q3 25 | -4.6% | -31.2% | ||
| Q2 25 | -1.4% | -37.3% | ||
| Q1 25 | -9.1% | -45.8% | ||
| Q4 24 | -11.6% | — | ||
| Q3 24 | -6.4% | -40.9% | ||
| Q2 24 | -2.8% | -80.2% | ||
| Q1 24 | -8.3% | -61.4% |
每股收益（稀释后）LEEZLAB
| Q4 25 | $-0.92 | $-0.05 | ||
| Q3 25 | $-1.02 | $-0.03 | ||
| Q2 25 | $-0.31 | $-0.04 | ||
| Q1 25 | $-2.07 | $-0.04 | ||
| Q4 24 | $-2.80 | $-0.09 | ||
| Q3 24 | $-1.68 | $-0.04 | ||
| Q2 24 | $-0.73 | $-0.08 | ||
| Q1 24 | $-2.06 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-48.7M | $715.5M |
| 总资产 | $592.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LEEZLAB
| Q4 25 | $12.6M | $689.6M | ||
| Q3 25 | $10.0M | $717.2M | ||
| Q2 25 | $14.1M | $732.2M | ||
| Q1 25 | $4.7M | $757.3M | ||
| Q4 24 | $6.1M | $779.7M | ||
| Q3 24 | $9.6M | $616.1M | ||
| Q2 24 | $13.4M | $630.0M | ||
| Q1 24 | $16.1M | $650.8M |
股东权益LEEZLAB
| Q4 25 | $-48.7M | $715.5M | ||
| Q3 25 | $-43.3M | $759.9M | ||
| Q2 25 | $-40.5M | $791.7M | ||
| Q1 25 | $-38.9M | $810.8M | ||
| Q4 24 | $-26.7M | $840.9M | ||
| Q3 24 | $-9.9M | $667.7M | ||
| Q2 24 | $4.0M | $704.2M | ||
| Q1 24 | $7.9M | $762.2M |
总资产LEEZLAB
| Q4 25 | $592.6M | $1.2B | ||
| Q3 25 | $601.7M | $1.2B | ||
| Q2 25 | $622.7M | $1.2B | ||
| Q1 25 | $623.9M | $1.2B | ||
| Q4 24 | $633.0M | $1.2B | ||
| Q3 24 | $649.2M | $985.3M | ||
| Q2 24 | $677.5M | $987.4M | ||
| Q1 24 | $684.8M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $3.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 2.9% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LEEZLAB
| Q4 25 | $4.5M | $-26.0M | ||
| Q3 25 | $-6.3M | $-32.0M | ||
| Q2 25 | $8.9M | $-31.0M | ||
| Q1 25 | $-790.0K | $-61.7M | ||
| Q4 24 | $-7.3M | $-55.8M | ||
| Q3 24 | $-261.0K | $-26.8M | ||
| Q2 24 | $-1.9M | $-42.2M | ||
| Q1 24 | $3.2M | $-90.1M |
自由现金流LEEZLAB
| Q4 25 | $3.7M | $-26.7M | ||
| Q3 25 | $-8.3M | $-35.0M | ||
| Q2 25 | $8.3M | $-33.9M | ||
| Q1 25 | $-2.2M | $-63.2M | ||
| Q4 24 | $-8.9M | $-58.4M | ||
| Q3 24 | $-2.9M | $-28.2M | ||
| Q2 24 | $-5.5M | $-42.9M | ||
| Q1 24 | $1.3M | $-91.1M |
自由现金流率LEEZLAB
| Q4 25 | 2.9% | -21.0% | ||
| Q3 25 | -6.0% | -30.4% | ||
| Q2 25 | 5.9% | -31.1% | ||
| Q1 25 | -1.6% | -59.9% | ||
| Q4 24 | -6.1% | -53.8% | ||
| Q3 24 | -1.8% | -27.7% | ||
| Q2 24 | -3.6% | -42.9% | ||
| Q1 24 | 0.9% | -104.5% |
资本支出强度LEEZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | 1.0% | 1.5% | ||
| Q4 24 | 1.1% | 2.4% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 2.4% | 0.7% | ||
| Q1 24 | 1.3% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LEE
| Advertising And Marketing Services | $60.0M | 46% |
| Subscription And Circulation | $57.7M | 44% |
| Other | $12.4M | 10% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
